Results 261 to 270 of about 59,251 (307)
European Journal of Heart Failure, 2019 To assess tolerability and optimal time point for initiation of sacubitril/valsartan in patients stabilised after acute heart failure (AHF).
Rolf Wachter +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
American Journal of Cardiovascular Drugs, 2002
Valsartan, an orally active nonpeptide angiotensin II (AII) receptor antagonist with selectivity for the AII type I (AT(1)) receptor subtype, has recently been approved by the US Food and Drug Administration for the treatment of patients with heart failure (New York Health Association class II-IV) who are intolerant of ACE-inhibitor therapy.
Keri, Wellington, Karen L, Goa
+5 more sources
Valsartan, an orally active nonpeptide angiotensin II (AII) receptor antagonist with selectivity for the AII type I (AT(1)) receptor subtype, has recently been approved by the US Food and Drug Administration for the treatment of patients with heart failure (New York Health Association class II-IV) who are intolerant of ACE-inhibitor therapy.
Keri, Wellington, Karen L, Goa
+5 more sources
Drugs, 1999
Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from those seen with HCTZ monotherapy. In
H D, Langtry, K J, McClellan
openaire +2 more sources
Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from those seen with HCTZ monotherapy. In
H D, Langtry, K J, McClellan
openaire +2 more sources
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
New England Journal of Medicine, 2001 J. Cohn, G. Tognoni
exaly +2 more sources
Circulation
BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction.
Robert Shaddy +39 more
semanticscholar +1 more source
BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction.
Robert Shaddy +39 more
semanticscholar +1 more source
European Journal of Heart Failure
The effects of initiating sacubitril/valsartan in patients with stable heart failure with reduced ejection fraction (HFrEF) on response to fluid and sodium expansion are unknown.
Alexandre Mebazaa +12 more
semanticscholar +1 more source
The effects of initiating sacubitril/valsartan in patients with stable heart failure with reduced ejection fraction (HFrEF) on response to fluid and sodium expansion are unknown.
Alexandre Mebazaa +12 more
semanticscholar +1 more source
Circulation
BACKGROUND: A hypothetical concern has been raised that sacubitril/valsartan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-β peptides in the brain, some of which are neurotoxic and linked to Alzheimer ...
P. Dewan +21 more
semanticscholar +1 more source
BACKGROUND: A hypothetical concern has been raised that sacubitril/valsartan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-β peptides in the brain, some of which are neurotoxic and linked to Alzheimer ...
P. Dewan +21 more
semanticscholar +1 more source